ToleraBio

Precision Immunology

Pre-clinical precision
immunology

Tolera Bio is advancing targeted approaches designed to support durable immune balance while preserving healthy immunity.

Contact Us Our Team

What We Do

Thoughtful science,
translational execution

Tolera Bio is a pre-clinical precision immunology company focused on advancing targeted strategies intended to support immune tolerance. Our work centers on thoughtful design and translational execution, with the goal of enabling clear decision-making from early research through pre-clinical development.

We build programs with rigorous attention to mechanism, safety, and clinical translatability — prioritizing depth of understanding over speed of activity, and long-term durability over short-term signal.

Antigen-Specific Approach

We pursue strategies designed for precision — targeting immune pathways with specificity intended to minimize off-target effects and support selective immune modulation.

Translational Mindset

Every program is designed with clinical translatability in mind — anchoring research decisions to the path from pre-clinical evidence to potential future study.

Safety by Design

Safety is not an afterthought. Our frameworks integrate mechanistic safety evaluation into program design from the earliest stages of research.

Scalable Development

We build operational and scientific infrastructure to support efficient CRO management, cross-functional execution, and program advancement at each pre-clinical milestone.

Proprietary Notice

Program-level scientific details — including targets, modalities, indications, and candidate data — are shared exclusively with qualified partners under a signed NDA. Contact us to begin a confidential conversation.

Current Stage

Pre-Clinical

Active research & development

Where We Are

Building the foundation
for future clinical readiness

  • Discovery and validation — Identifying and characterizing biological hypotheses through rigorous mechanistic studies and model-based evidence generation.
  • Pre-clinical studies — Conducting structured in vitro and in vivo experiments to build the body of evidence needed to understand safety, activity, and biological plausibility.
  • IND-enabling planning — Evaluating the scientific and operational requirements associated with IND-enabling work as part of long-term program strategy.

Forward-looking statements and any implied timelines reflect current planning and are subject to change based on scientific, regulatory, and operational developments.

Leadership

Our Team

Full bios and CVs available upon request.

RE

Reema Eid

Scientific Strategist

  • Experience in translational research strategy, bridging early biology to development-stage decision frameworks.
  • Background in cross-functional program execution and alignment across scientific and operational teams.
  • Track record of CRO relationship management, study design oversight, and pre-clinical program advancement.
JV

Jonathan Villanueva

Founder

  • Founded Tolera Bio to advance precision immunology programs from concept through disciplined pre-clinical development.
  • Experience in research operations, strategic planning, and building scientific infrastructure for early-stage biotech.
  • Focused on creating organizational clarity and scientific rigor at the foundation of each program decision.

Interested in full bios or CVs? Contact us at contact@tolerabio.com — we share detailed backgrounds with qualified partners and collaborators.

Get in Touch

Let's start a conversation

We welcome inquiries from potential partners, collaborators, and investors. Program-specific details are shared under NDA with qualified parties.

contact@tolerabio.com